Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lumateperone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 18/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 4/20 | 1.00 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.83 |
| ▸ | HTR2C | P28335 | 15/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | DRD4 | P21917 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 1/20 | 1.00 |
| ▸ | CCR3 | P51677 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lumateperone SCHEMBL29558708 | 1.00 | HTR2A (1.00) | HTR2AHTR2CSLC6A4HTR1ADRD1 | |
| Lumateperone SCHEMBL29355976 | 1.00 | HTR2A (1.00) | HTR2AHTR2CSLC6A4HTR1ADRD1 | |
| Lumateperone SCHEMBL22635597 | 0.96 | HTR2A (0.91) | HTR2AHTR2CSLC6A4HTR1ADRD1 | |
| Lumateperone SCHEMBL31465557 | 0.96 | HTR2A (0.91) | HTR2AHTR2CSLC6A4HTR1ADRD1 | |
| Lumateperone SCHEMBL21996433 | 0.94 | HTR2A (0.88) | HTR2AHTR2CSLC6A4HTR1ADRD1 | |
| Lumateperone SCHEMBL31032326 | 0.94 | HTR2A (0.88) | HTR2AHTR2CSLC6A4HTR1ADRD1 | |
| Lumateperone SCHEMBL16005572 | 0.91 | HTR2A (0.90) | HTR2AHTR2CSLC6A4HTR1ADRD1 | |
| Lumateperone SCHEMBL22067597 | 0.91 | HTR2A (1.00) | HTR2AHTR2CSLC6A4HTR1ADRD1 | |
| Lumateperone SCHEMBL21524899 | 0.91 | HTR2A (1.00) | HTR2AHTR2CSLC6A4HTR1ADRD1 | |
| Lumateperone SCHEMBL17681371 | 0.91 | HTR2A (1.00) | HTR2AHTR2CSLC6A4HTR1ADRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE48825-E1 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-11-23 | — | — | US | claimed |
| US-9586960-B2 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms | INTRA-CELLULAR THERAPIES, INC. (US) | 2017-03-07 | — | — | US | claimed |
| US-9199995-B2 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-12-01 | — | — | US | claimed |
| US-20140323491-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SOLID | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-10-30 | — | — | US | claimed |
| US-8648077-B2 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-02-11 | — | — | US | claimed |
| US-20110112105-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SOLID | INTRA-CELLULAR THERAPIES, INC. | 2011-05-12 | — | — | US | claimed |
| EP-3609891-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA CELLULAR THERAPIES INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20240327409-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2024-10-03 | — | — | US | disclosed |
| CN-114105980-B | Preparation method of Lu Meipai-one intermediate compound and lumepiquat chloride intermediate compound | 南方科技大学坪山生物医药研究院 | 2024-04-16 | — | — | CN | disclosed |
| US-20230382914-A1 | SOLID STATE FORMS OF LUMATEPERONE DITOSYLATE SALT | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-11-30 | — | — | US | disclosed |
| WO-2023195027-A1 | PROCESS FOR THE PREPARATION OF 4-((6BR,10AS)-3-METHYL-2,3,6B,9,10,10A-HEXAHYDRO-1H,7H-PYRIDO[3',4':4,5]PYRROLO[1,2,3-DE]QUINOXALIN-8-YL)-1-(4-FLUORO-PHENYL)-BUTAN-1-ONE AND INTERMEDIATES THEREOF | MSN LABORATORIES PRIVATE LIMITED, R&D CENTER (IN) | 2023-10-12 | — | — | WO | disclosed |
| US-11760757-B2 | Solid state forms of lumateperone ditosylate salt | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2023-09-19 | — | — | US | disclosed |
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | INTRA-CELLULAR THERAPIES, INC. | 2023-01-12 | — | — | US | disclosed |
| EP-2262505-B1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SOLID | INTRA CELLULAR THERAPIES INC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8648077-B2 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-8648077-B2 | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-02-11 | — | — | US | disclosed |
| US-20130202692-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2013-08-08 | — | — | US | disclosed |
| US-20110112105-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SOLID | INTRA-CELLULAR THERAPIES, INC. | 2011-05-12 | — | — | US | disclosed |
| EP-2262505-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SOLID | Intra-Cellular Therapies, Inc. (US) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009114181-A2 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SOLID | INTRA-CELLULAR THERAPIES, INC. (US) | 2009-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11760757-B2 | Solid state forms of lumateperone ditosylate salt | LSS, DHPS, LPXN | HTR2A 1890/4885SLC6A4 215/4885DRD2 1115/4885 |
| US-20240327409-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | HTR2A 1243/4885SLC6A4 4002/4885DRD2 221/4885 |
| US-20110112105-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SOLID | TST, POLL, SLC6A12 | HTR2A 1150/4885SLC6A4 477/4885DRD2 469/4885 |
| US-20140323491-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SOLID | TST, POLL, SLC6A12 | HTR2A 1150/4885SLC6A4 477/4885DRD2 469/4885 |
| US-20130202692-A1 | ORGANIC COMPOUNDS | HTR2C, HTR2A, HTR3A | HTR2A 2/4885SLC6A4 8/4885DRD2 29/4885 |
| US-20230009130-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SYNTHESIS | HCCS, CYCS, CBR3 | HTR2A 1243/4885SLC6A4 4002/4885DRD2 221/4885 |
| US-20230382914-A1 | SOLID STATE FORMS OF LUMATEPERONE DITOSYLATE SALT | LSS, DHPS, LPXN | HTR2A 1890/4885SLC6A4 215/4885DRD2 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.